

Entheon Adopts Restricted Share Unit Plan

Vancouver, British Columbia--(October 21, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that the Board of Directors have approved the adoption of a 10% rolling Restricted Share Unit Plan whereby the Company may issue up to 10% of its issued capital as Restricted Share Units to eligible directors, officers, employees and consultants. The Restricted Share Unit Plan was adopted by the Company to provide incentives to its executives and service providers and to better align interests with shareholders while preserving the Company's cash for furthering its business.

At the next annual general and special meeting of shareholders on November 19, 2021, the Company will ask shareholders to ratify and confirm the adoption of the Restricted Share Unit Plan.

**On Behalf of the Board of Directors,
Timothy Ko, CEO**

For more information, please contact the Company at:

Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
joe@entheonbiomedical.com
<https://entheonbiomedical.com/>

For media inquiries, please contact Crystal Quast at:

Bullseye Corporate
Crystal Quast
Telephone: +1 (647) 529-6364
quast@bullseyecorporate.com

Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.